导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.56% | 2758/4773 |
| 近一周 | -1.78% | 3336/5467 |
| 近一月 | -5.37% | 2363/5421 |
| 近一季 | -7.87% | 2513/5238 |
| 近半年 | -1.85% | 2109/4931 |
| 近一年 | 0.59% | 2455/4400 |
| 近两年 | 45.91% | 1613/2954 |
| 近三年 | 28.28% | 1132/2253 |
| 成立以来 | 65.22% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.60% 3302/4961 |
12.15% 2219/5312 |
- - |
- - |
| 2025 | 19.61% 2200/4813 |
-1.01% 2533/3635 |
2.18% 1790/4076 |
17.93% 2392/4524 |
0.28% 2088/4813 |
| 2024 | 17.06% 733/3463 |
2.82% 693/2808 |
-1.14% 946/3014 |
16.76% 1357/3129 |
-1.38% 1676/3463 |
| 2023 | -8.81% 1060/2656 |
4.40% 962/2280 |
-3.87% 939/2385 |
-2.84% 763/2515 |
-6.48% 1794/2655 |
| 2022 | -18.97% 784/2207 |
-13.78% 836/1919 |
6.83% 597/2016 |
-13.51% 914/2113 |
1.72% 1166/2208 |
| 2021 | -2.91% 878/1822 |
-2.72% 695/1255 |
4.16% 915/1330 |
-5.52% 817/1466 |
1.42% 940/1822 |
| 2020 | 30.51% 521/1250 |
-9.43% 675/1028 |
13.28% 631/1067 |
12.50% 382/1164 |
13.06% 399/1184 |
| 2019 | 36.89% 348/1092 |
26.72% 381/754 |
0.01% 205/804 |
1.31% 414/850 |
6.63% 579/918 |
| 2018 | -22.61% 250/834 |
- - |
- - |
- - |
-11.54% 313/691 |
| 2017 | 21.92% 158/714 |
- - |
- - |
- - |
- - |
| 2016 | -9.71% 269/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.6144 | 32.25% |
| 景顺长城中证港股通创新药ETF | 1.6764 | 32.17% |
| 港股医疗 | 0.9539 | 31.90% |
| 港股医疗ETF | 1.4546 | 31.90% |
| 港股通医疗ETF工银 | 0.9639 | 31.81% |
| 港股通医疗ETF华宝 | 0.9752 | 31.64% |
| 万家中证港股通创新药ETF发起式联接A | 1.4069 | 31.06% |
| 万家中证港股通创新药ETF发起式联接C | 1.4061 | 30.98% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 嘉实中证港股通创新药指数发起式A | 0.8590 | 30.57% |
| 天弘沪深300ETF联接A VS. 长安沪深300非周期A(740101) |